CY1115877T1 - Συνθεσεις που περιλαμβανουν (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1η-pyrazol-4-yl)-phenyl]-ethanol σαν παραγοντα τροποποιησης kinασων (kinases) πρωτεϊνης - Google Patents

Συνθεσεις που περιλαμβανουν (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1η-pyrazol-4-yl)-phenyl]-ethanol σαν παραγοντα τροποποιησης kinασων (kinases) πρωτεϊνης

Info

Publication number
CY1115877T1
CY1115877T1 CY20141100938T CY141100938T CY1115877T1 CY 1115877 T1 CY1115877 T1 CY 1115877T1 CY 20141100938 T CY20141100938 T CY 20141100938T CY 141100938 T CY141100938 T CY 141100938T CY 1115877 T1 CY1115877 T1 CY 1115877T1
Authority
CY
Cyprus
Prior art keywords
phenyl
chinese
pyrazol
ethanol
amino
Prior art date
Application number
CY20141100938T
Other languages
Greek (el)
English (en)
Inventor
Steven John Woodhead
David Charles Rees
Martyn Frederickson
Kyla Merriom Grimshaw
Original Assignee
Astex Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Limited filed Critical Astex Therapeutics Limited
Publication of CY1115877T1 publication Critical patent/CY1115877T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CY20141100938T 2007-03-14 2014-11-12 Συνθεσεις που περιλαμβανουν (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1η-pyrazol-4-yl)-phenyl]-ethanol σαν παραγοντα τροποποιησης kinασων (kinases) πρωτεϊνης CY1115877T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89475207P 2007-03-14 2007-03-14
GBGB0704932.3A GB0704932D0 (en) 2007-03-14 2007-03-14 Pharmaceutical compounds
EP08719025.2A EP2134339B1 (en) 2007-03-14 2008-03-14 Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases

Publications (1)

Publication Number Publication Date
CY1115877T1 true CY1115877T1 (el) 2017-01-25

Family

ID=38008428

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100938T CY1115877T1 (el) 2007-03-14 2014-11-12 Συνθεσεις που περιλαμβανουν (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1η-pyrazol-4-yl)-phenyl]-ethanol σαν παραγοντα τροποποιησης kinασων (kinases) πρωτεϊνης

Country Status (23)

Country Link
US (2) US20100113551A1 (enExample)
EP (2) EP2433632A1 (enExample)
JP (2) JP2010521446A (enExample)
KR (1) KR20100014720A (enExample)
CN (1) CN101686965B (enExample)
AU (1) AU2008224657B2 (enExample)
BR (1) BRPI0808802A2 (enExample)
CA (1) CA2679878A1 (enExample)
CY (1) CY1115877T1 (enExample)
DK (1) DK2134339T3 (enExample)
ES (1) ES2511817T3 (enExample)
GB (1) GB0704932D0 (enExample)
HR (1) HRP20141034T1 (enExample)
IL (1) IL200822A (enExample)
MX (1) MX2009009874A (enExample)
NZ (1) NZ579341A (enExample)
PL (1) PL2134339T3 (enExample)
PT (1) PT2134339E (enExample)
RS (1) RS53580B1 (enExample)
RU (1) RU2527151C2 (enExample)
SI (1) SI2134339T1 (enExample)
WO (1) WO2008110846A2 (enExample)
ZA (1) ZA200906303B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
JOP20190231A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用
RU2657832C1 (ru) * 2017-06-07 2018-06-15 федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" Антидиабетическое средство
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
MX2022011519A (es) * 2020-03-25 2022-10-07 Woolsey Pharmaceuticals Inc Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal.
CN111707830B (zh) * 2020-07-16 2023-08-15 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肺损害中的应用
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
EP0457803A4 (en) 1989-02-08 1991-12-04 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5049570A (en) 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5532356A (en) 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0891343A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB2314327B (en) 1996-04-30 2000-07-12 Kodak Ltd Pyrazolone image dye-forming couplers
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
GB9700555D0 (en) 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
BR9908522A (pt) 1998-01-29 2001-10-02 Viropharma Inc Composto, pró-droga, intermediário para a preparação de um composto, composição farmacêutica, processos para tratar e prevenir infecção por pneumovìrus, para tratar células em cultura, para tratar materiais biológicos, e, para preparar um composto
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6503905B1 (en) 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
NZ515460A (en) 1999-05-14 2004-06-25 Neurocrine Biosciences Inc Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
IL148698A0 (en) 1999-09-17 2002-09-12 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
MX226123B (es) 1999-09-17 2005-02-07 Millennium Pharm Inc Benzamidas e inhibidores del factor xa relacionadas.
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
MXPA03009847A (es) 2001-04-27 2004-02-12 Vertex Pharma Inhibidores de cinasa derivados de pirazol.
MXPA04001087A (es) 2001-08-03 2004-07-08 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
FR2830192B1 (fr) 2001-09-28 2004-08-20 Oreal Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
DE60330126D1 (de) 2002-02-14 2009-12-31 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
NZ535603A (en) 2002-03-20 2007-10-26 Metabolex Inc Substituted phenylacetic acids
WO2003086247A1 (en) 2002-04-08 2003-10-23 Barosense, Inc. Satiation devices and methods
WO2003090680A2 (en) 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
DK1542997T3 (da) 2002-07-24 2012-06-25 Dermira Canada Inc Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
MXPA05002983A (es) 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
KR101163800B1 (ko) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 신규 인다졸 유도체
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
RU2419612C2 (ru) * 2003-12-23 2011-05-27 Астекс Терапьютикс Лимитед Производные пиразола в качестве модуляторов протеинкиназы
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
GB2427406A (en) 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
AR054485A1 (es) * 2005-06-21 2007-06-27 Cancer Rec Tech Ltd ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) * 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
ZA200906303B (en) 2015-08-26
NZ579341A (en) 2012-08-31
CN101686965B (zh) 2014-09-17
CA2679878A1 (en) 2008-09-18
WO2008110846A2 (en) 2008-09-18
AU2008224657A1 (en) 2008-09-18
MX2009009874A (es) 2009-09-24
HRP20141034T1 (hr) 2014-12-19
BRPI0808802A2 (pt) 2017-05-02
RS53580B1 (sr) 2015-02-27
SI2134339T1 (sl) 2014-12-31
RU2009137779A (ru) 2011-05-10
EP2433632A1 (en) 2012-03-28
ES2511817T3 (es) 2014-10-23
KR20100014720A (ko) 2010-02-10
PT2134339E (pt) 2014-11-03
PL2134339T3 (pl) 2015-04-30
EP2134339B1 (en) 2014-09-17
GB0704932D0 (en) 2007-04-25
CN101686965A (zh) 2010-03-31
WO2008110846A3 (en) 2009-03-05
US20110269808A1 (en) 2011-11-03
JP2010521446A (ja) 2010-06-24
US20100113551A1 (en) 2010-05-06
RU2527151C2 (ru) 2014-08-27
AU2008224657B2 (en) 2014-06-26
IL200822A0 (en) 2010-05-17
DK2134339T3 (da) 2014-11-03
JP2015028033A (ja) 2015-02-12
EP2134339A2 (en) 2009-12-23
IL200822A (en) 2016-09-29
US8497294B2 (en) 2013-07-30
HK1133828A1 (en) 2010-04-09

Similar Documents

Publication Publication Date Title
CY1115877T1 (el) Συνθεσεις που περιλαμβανουν (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1η-pyrazol-4-yl)-phenyl]-ethanol σαν παραγοντα τροποποιησης kinασων (kinases) πρωτεϊνης
NO20070162L (no) Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino- 1-etyl-2-metylpropyl)-fenol-hydroklorid
BR112012028842A2 (pt) "composições de massa frágil e métodos para fazer e usar a mesma"
DOP2014000135A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
BRPI0914606A2 (pt) Mistura para controlar fungos nocivos fitopatogênicos, composição, método para controlar fungos nocivos fitopatogênicos, semente, e, uso dos componentes.
CY1112635T1 (el) 1-[2-(2,4-διμεθυλφαινυλσουλφανυλ)-φαινυλ]πιπεραζινη ως μια ενωση με συνδυασμενη δραστικοτητα επαναπροσληψης σεροτονινης, 5-ητ3 και 5-ητ1α για τη θεραπεια γνωστικης εξασθενησης
ATE478850T1 (de) Herstellung von eslicarbazepin und verwandten verbindungen mittels asymmetrischer hydrierung
BRPI0913295A2 (pt) processos para a preparação de uma composição de um dióxido de titânio e para a produção de um substrato revestido, composição de um dióxido de titânio, composição aglutinante, composição para revestimento, e, usos de um revestimento, de uma composição aglutinante, e de uma composição de dióxido de titânio, e, substrato revestido.
AR065467A1 (es) Composiciones de tabaco y metodos de preparacion
BRPI0820578A2 (pt) Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças
CL2009000443A1 (es) Compuestos derivados de 3-metil-imidazo-[1,2-b]-piridazina, moduladores de cinasa de tirosina c-met; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades proliferativas como tumores solidos, metastasis, cancer renal, cancer de cabeza y cuello. cancer pulmon.
ATE447546T1 (de) Verfahren zur herstellung einer cinacalcetbase
IL206197A0 (en) Crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
BRPI0916069B8 (pt) composto, usos de um composto e composição farmacêutica
CL2008002450A1 (es) Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras.
BRPI0923291A2 (pt) processo para a destilação de uma mistura aquosa de polimetilol, composição, e, uso de um polimetilol.
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BRPI0820962A2 (pt) Compostos, processo para preparar compostos, composição agrícola, método para combater fungos fitopatogênicos nocivos, uso de compostos, e, sementes
IL323982A (en) Oxazolidinone compounds, liposome formulations containing oxazolidinone compounds and methods of using them
BR112018007784A2 (pt) uso de uma composição de revestimento, métodos para revestir uma placa de fibrocimento e para produzir uma dispersão polimérica aquosa, e, dispersão polimérica aquosa
WO2009137714A3 (en) Forms of lapatinib ditosylate and processes for preparation thereof
BRPI0917235A2 (pt) dissulfeto de dimetila, processo para preparação de dissulfeto de dimetila, composição à base de dissulfeto de dimetila, utilização do dissulfeto de dimetila, e, ácido metanossulfônico.
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
BRPI0518043A (pt) tetraidroisoquinolinas substituìdas por 4-fenila e uso destas para bloquear a recaptação de norepinefrina, dopamina e serotonina
MX2015015052A (es) Derivados de isoquinolina que estimulan la neurogenesis.